

Publikationsliste M Klinger

- 1: Jabłońska A, Zagraban B, Neumayer C, **Klinger M**, Eilenberg W, Nanobachvili J, Paradowska E, Brostjan C, Huk I. Polymorphisms Are Associated with the Occurrence of Abdominal Aortic Aneurysm. *J Immunol*. 2020 Jun 1;204(11):2900-2909.
- 2: Jabłońska A, Neumayer C, Bolliger M, Burghuber C, **Klinger M**, Demyanets S, Nanobachvili J, Huk I. Insight into the expression of toll-like receptors 2 and 4 in patients with abdominal aortic aneurysm. *Mol Biol Rep*. 2020 Apr;47(4):2685-2692.
- 3: Jabłońska A, Neumayer C, Bolliger M, Gollackner B, **Klinger M**, Paradowska E, Nanobachvili J, Huk I. Analysis of host Toll-like receptor 3 and RIG-I-like receptor gene expression in patients with abdominal aortic aneurysm. *J Vasc Surg*. 2018 Dec;68(6S):39S-46S.
- 4: Eilenberg W, Stojkovic S, Kaider A, Kozakowski N, Domenig CM, Burghuber C, Nanobachvili J, Huber K, **Klinger M**, Neumayer C, Huk I, Wojta J, Demyanets S. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. *Clin Chem Lab Med*. 2017 Nov 27;56(1):147-156.
- 5: Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Gröger M, **Klinger M**, Wojta J, Neumayer C, Huk I, Demyanets S. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Associated with Symptomatic Carotid Atherosclerosis and Drives Pro-inflammatory State In Vitro. *Eur J Vasc Endovasc Surg*. 2016 May;51(5):623-31.
- 6: Piechota-Polanczyk A, Demyanets S, Nykonenko O, Huk I, Mittlboeck M, Domenig CM, Neumayer C, Wojta J, Nanobachvili J, **Klinger M**. Decreased tissue levels of cyclophilin A, a cyclosporine a target and phospho-ERK1/2 in simvastatin patients with abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 2013 Jun;45(6):682-8.
- 7: Piechota-Polanczyk A, Goraca A, Demyanets S, Mittlboeck M, Domenig C, Neumayer C, Wojta J, Nanobachvili J, Huk I, **Klinger M**. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF- κ B. *Eur J Vasc Endovasc Surg*. 2012 Aug;44(2):133-7.
- 8: Tamandl D, **Klinger M**, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, Gruenberger T. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. *Ann Surg Oncol*. 2011 Feb;18(2):421-30.
- 9: Tamandl D, Gruenberger B, **Klinger M**, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. *Ann Surg*. 2010 Jul;252(1):124-30.

- 10: **Klinger M**, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. *Ann Surg Oncol*. 2010 Aug;17(8):2059-65.
- 11: **Klinger M**, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. *Eur J Surg Oncol*. 2009 May;35(5):515-20.
- 12: Tamandl D, Herberger B, Gruenberger B, Puhalla H, **Klinger M**, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. *Ann Surg Oncol*. 2008 Oct;15(10):2787-94.
- 13: Kandutsch S, **Klinger M**, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. *Eur J Surg Oncol*. 2008 Nov;34(11):1231-6.
- 14: Farhan H, Schuster C, **Klinger M**, Weisz E, Waxenecker G, Schuster M, Sexl V, Mudde GC, Freissmuth M, Kircheis R. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. *J Pharmacol Exp Ther*. 2006 Dec;319(3):1459-66.
- 15: **Klinger M**, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. *Cancer Res*. 2004 Feb 1;64(3):1087-93.
- 16: Kudlacek O, Just H, Korkhov VM, Vartian N, **Klinger M**, Pankevych H, Yang Q, Nanoff C, Freissmuth M, Boehm S. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. *Neuropsychopharmacology*. 2003 Jul;28(7):1317-27.
- 17: **Klinger M**, Kuhn M, Just H, Stefan E, Palmer T, Freissmuth M, Nanoff C. Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation. *Naunyn-Schmiedeberg's Arch Pharmacol*. 2002 Oct;366(4):287-98.
- 18: **Klinger M**, Kudlacek O, Seidel MG, Freissmuth M, Sexl V. MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. *J Biol Chem*. 2002 Sep 6;277(36):32490-7.
- 19: **Klinger M**, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. *Cell Signal*. 2002 Feb;14(2):99-108.

20: **Klinger M**, Bofill-Cardona E, Mayer B, Nanoff C, Freissmuth M, Hohenegger M. Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. *Biochem J*. 2001 May 1;355(Pt 3):827-33.

21: Seidel MG, **Klinger M**, Freissmuth M, Höller C. Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. *J Biol Chem*. 1999 Sep 3;274(36):25833-41.

22: **Klinger M**, Freissmuth M, Nickel P, Stäbler-Schwarzbart M, Kassack M, Suko J, Hohenegger M. Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site. *Mol Pharmacol*. 1999 Mar;55(3):462-72.